ALBAWABA - The US Food and Drug Administration (FDA) has approved generic Vyvanse medications for the treatment of ADHD for ages six years old and up, making it easier to access more affordable options.
Vyvanse, a commonly prescribed medication produced in Japan is currently in short supply due to the increased demand and delays in delivery. However, drug manufacturers in America, Britain, and India have started shipping generic versions of Vyvanse.
ADHD is a common disorder that affects millions of children worldwide, resulting in symptoms such as inattention, hyperactivity, and impulsivity, it often persists into the adult years.
Shutterstock
The FDA's recent approval of a generic version of Vyvanse may help alleviate concerns about medication shortages and offer more options for treatment.
Generic drugs are typically less expensive than brand-name products, making them more accessible to patients who may have difficulty affording the original medication.
With the creation of generic versions of Vyvanse, patients may be able to find more cost-effective options for treatment, reducing the financial burden of managing ADHD.
Shutterstock
On August 28 of last year, the US Food and Drug Administration granted approval for many initial generic drugs, thereby allowing the creation of "generic drugs." The drug will be produced in the form of chewable tablets and capsules, as per the report.
There also might be some authorized generic medications that'll be utilized to treat moderate to severe binge eating disorder (BED) among adults, as well as attention-deficit/hyperactivity disorder (ADHD) in children aged six and up.
Know more about Vyvanse here.
